Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: SKX third-largest global footwear brand at $8.97B FY2024 revenue with 5,000+ stores; 3G Capital announced ~$9.4B take-private in May 2025 competing with Nike and Adidas for athletic and comfort footwear.
Skechers U.S.A., Inc. is a Manhattan Beach, California-based global footwear brand — listed on NYSE (NYSE: SKX) — designing and marketing performance athletic shoes, casual lifestyle sneakers, and work boots for men, women, and children across 180+ countries through 5,000+ company-owned retail stores, department stores, specialty footwear retailers, and e-commerce channels, generating $8.97 billion in net sales in fiscal year 2024 (+12.1% year-over-year) as the third-largest athletic footwear brand globally (behind Nike and Adidas). Founded in 1992 by Robert Greenberg and his son Michael Greenberg, Skechers built its identity on comfort technologies (Air-Cooled Memory Foam, Arch Fit, Relaxed Fit), affordable pricing relative to Nike and Adidas, and broad demographic appeal across kids (Twinkle Toes, S-Lights), adults (walking, running, lifestyle), seniors (Arch Fit Go Walk), and work/safety categories.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.